NovoTTF-100A Provides Non-invasive Treatment Options for Recurrent Glioblastomas

The NovoTTF-100A system is a portable, non-invasive medical device that slows and reverses tumor growth by creating low intensity, alternating electric fields within the tumor. In this study, continuous NovoTTF-100A monotherapy (20-24 hours per day, 7 days a week) was compared with the best standard of care chemotherapy (based on the physician choice).
The 3yr overall survival for the NovoTTF-100A group was 8% compared to 1% for the chemotherapy group. Furthermore, the patients treated with NovoTTF-100A had improved the 6mth progression free survival rates (21.4% compared to 15.2%) and more patients had reduced tumor growth (14% compared to 9.6% for chemotherapy).

I like this approach because the NovoTTF provides benefits that are improved or comparable with active chemotherapy, but without any of the harsh and damaging side effects. Furthermore, it provides a new glioblastoma treatment option for patients with recurrent tumors, as well as for patients with chemotherapy resistant tumors, or those wanting to avoid chemotherapy.
Updated Survival Data from Study Comparing TTF (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology.

Speak Your Mind